To explore the mechanism of CXCL14 in NF-κB activation, treating lung cancer cells with PLCβ3, PKCα, c-Src inhibitors reversed CXCL14-mediated activation of p65 (Figure 6A-B). The gene discussed is PLCB3; the disease is lung carcinoma.